Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsFRA:9BK0 50 FCF Margin % is 15.51% as of Dec. 2025. GuruFocus rates FRA:9BK0 with a GF Score™ of 50/100 and a GF Value™ of €7.32 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 73.95% on this metric.
The historical rank and industry rank for ABL Diagnostics's FCF Margin % or its related term are showing as below:
FRA:9BK0'
s FCF Margin % Range Over the Past 10 Years
Min: -164.14 Med: -16.58 Max: 56.4
Current: 10.29
During the past 13 years, the highest FCF Margin % of ABL Diagnostics was 56.40%. The lowest was -164.14%. And the median was -16.58%.
FRA:9BK0's FCF Margin % is ranked better than 73.95% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 3.365
vs FRA:9BK0: 10.29
ABL Diagnostics FCF Margin % Related Terms
ABL Diagnostics FCF Margin % Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9BK0 vs VEEV, BTSG, TEM: FCF Margin % Comparison
For the Health Information Services subindustry, ABL Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (FRA:9BK0) has a FCF Margin % of 15.51% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ABL Diagnostics and its competitors. According to the industry distribution chart, ABL Diagnostics ranks #174 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 26%.
Is ABL Diagnostics' FCF Margin % too high?
ABL Diagnostics' current FCF Margin % is 15.51%. The Healthcare Providers & Services industry median FCF Margin % is 3.37. ABL Diagnostics' value of 15.51% is 360.9% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #174 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' FCF Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #174 out of 668 companies for FCF Margin %. This puts ABL Diagnostics in the upper half of its industry. The industry median FCF Margin % is 3.37. ABL Diagnostics' value of 15.51% is 360.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.37, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current FCF Margin % of 15.51% is 360.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current FCF Margin % is 15.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (FRA:9BK0) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.32, compared to a current price of €2.76 — trading 62.3% below its estimated fair value. The current FCF Margin % is 15.51% and 360.9% above the Healthcare Providers & Services industry median of 3.37. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For ABL Diagnostics (FRA:9BK0), the current FCF Margin % is 15.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (FRA:9BK0) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.76 is trading 62.3% below its estimated GF Value™ of €7.32.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for FRA:9BK0:
FCF Margin %: 15.51%
GF Value™: €7.32 vs. price of €2.76 (62.3% below fair value)
Industry Position: 360.9% above the Healthcare Providers & Services median (#174 of 668)
No single metric tells the full story. See the FRA:9BK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for FRA:9BK0
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9BK0 has been successfully added to your 
